ADC Therapeutics' (ADCT) recent restructuring improved the company's financial position and its Lotis-7 data looked encouraging, but outlook for revenue growth remains unclear given the competitive landscape in diffuse large B-cell lymphoma, RBC Capital Markets said in a note Monday.
The company reported Q3 revenue at the high end of Zynlonta's historical range, as previously announced, while maintaining good control over expenses, the investment firm said.
The company has a potential path forward, but the Lotis-7 data remains immature, RBC said, adding that additional data from subgroups could help contextualize the drug in the "highly competitive" DLBCL landscape.
RBC Capital Markets has a sector perform, speculative risk rating on ADC Therapeutics, with a $2 price target.
Shares of ADC Therapeutics were down 9.6% in Tuesday trading.
Price: 1.51, Change: -0.16, Percent Change: -9.58
Comments